Aethlon Medical Inc., a medical therapeutic company focused on developing products for cancer and life-threatening infectious diseases, has announced the publication of preclinical data showcasing the Hemopurifier®'s ability to remove platelet-derived extracellular vesicles (PD-EVs) from plasma. This breakthrough supports their ongoing oncology clinical trial in Australia, as PD-EVs are known to contribute to the spread of cancer. The study, published on bioRxiv, highlights the Hemopurifier's potential across multiple indications, suggesting a "pipeline within a device" approach for future therapeutic applications. Aethlon Medical plans to submit these findings to a peer-reviewed journal and further investigate PD-EV removal in diseases of interest.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。